Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

Brilacidin is being evaluated for PROPHYLAXIS not CURATIVE

Published 30 June 2022

This previous findings were confirmed by Xu, et al. [2], who further, specified that the protective effect of brilacidin is more likely to be preventive than curative, as brilacidin has no inhibition/protective effect after SARS-CoV-2-cell attachment, but only can inhibit SARS-CoV-2 entry into cells...

To sum up, these three studies demonstrated that brilacidin, a potent antibacterial synthetic HDP mimetic efficiently prevents SARS-CoV-2 entry into cells through interaction with both host cell surface HSPG and SARSCoV-2 N or M proteins to block viral attachment deactivate viral particles, respectively, and its antiviral activity is broaden to SARS-CoV-2 variants and other HCoVs. This broad-spectrum dual antiviral mechanism of action, which is enhanced when combined with Remdesivir, could break the transmission chain of SARS-CoV-2 and reduce emergence of SARS-CoV-2 resistant variant development.

https://www.jelsciences.com/articles/jbres1504.pdf

The Brilacidin-COVID clinical trial showed that "B" had no CURATIVE properties but what many fail to recognize is that this same clinical trial also showed that "B" has PREVENTIVE properties:

If a patient started study treatment within fewer than 7 days of onset of COVID-19 symptoms, patients in the Brilacidin 5-dose group achieved sustained recovery more quickly compared to the pooled placebo group (p=0.03). For this patient population, early treatment with Brilacidin from onset of symptoms appeared to have a potential positive impact on time to sustained recovery (the study’s primary endpoint), suggesting cases that can be treated close to initial onset of disease may be an attractive population to target for Brilacidin treatment.

http://www.ipharminc.com/press-release/2022/3/7/innovation-pharmaceuticals-reports-additional-findings-based-on-review-of-brilacidin-phase-2-covid-19-trial-results-and-compassionate-use-cases

NIAID is developing Brilacidin as a PROPHYLACTIC (preventive) COVID antiviral, based on the evidence, and pointing to Brilacidin's failure to CURE COVID, as evidenced in the P-2, is irrelevant to Brilacidin's perceived role as a COVID prophylactic, where its role will be to PREVENT COVID.

Message in reply to:
"-With Remdisivir (Gilead), Brilacidin increases effectiveness of treatment from 50% to 95%."

Then what happened here, when that was finally put to the test where it really counts?
https://clinicaltrials.gov/ct2/show/results/NCT04784897?term=brilacidin&draw=2&rank=2

When was the last time the Company itself decided it was okay to refer back to that pre-clinical statistic?
I believe it was 2020. And I'm guessing the reason for that is because the clinical results rendered it a misleading and meaningless statement when made in the absence of the context in which it was made as was done in your post. It's not in the Company's interests to refer to it...they know better.